TW224471B - - Google Patents

Info

Publication number
TW224471B
TW224471B TW081109247A TW81109247A TW224471B TW 224471 B TW224471 B TW 224471B TW 081109247 A TW081109247 A TW 081109247A TW 81109247 A TW81109247 A TW 81109247A TW 224471 B TW224471 B TW 224471B
Authority
TW
Taiwan
Application number
TW081109247A
Other languages
Chinese (zh)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of TW224471B publication Critical patent/TW224471B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW081109247A 1991-11-26 1992-11-18 TW224471B (cg-RX-API-DMAC7.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80116391A 1991-11-26 1991-11-26

Publications (1)

Publication Number Publication Date
TW224471B true TW224471B (cg-RX-API-DMAC7.html) 1994-06-01

Family

ID=25180362

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081109247A TW224471B (cg-RX-API-DMAC7.html) 1991-11-26 1992-11-18

Country Status (17)

Country Link
US (2) US5491216A (cg-RX-API-DMAC7.html)
EP (1) EP0544466A1 (cg-RX-API-DMAC7.html)
JP (1) JP3304442B2 (cg-RX-API-DMAC7.html)
KR (1) KR930009591A (cg-RX-API-DMAC7.html)
CN (1) CN1072723A (cg-RX-API-DMAC7.html)
AU (1) AU2857692A (cg-RX-API-DMAC7.html)
BR (1) BR9204542A (cg-RX-API-DMAC7.html)
CA (1) CA2083360A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ342492A3 (cg-RX-API-DMAC7.html)
FI (1) FI925343A7 (cg-RX-API-DMAC7.html)
HU (2) HU9203688D0 (cg-RX-API-DMAC7.html)
IL (1) IL103849A0 (cg-RX-API-DMAC7.html)
MX (1) MX9206724A (cg-RX-API-DMAC7.html)
NO (1) NO924525L (cg-RX-API-DMAC7.html)
NZ (1) NZ245170A (cg-RX-API-DMAC7.html)
TW (1) TW224471B (cg-RX-API-DMAC7.html)
ZA (1) ZA928916B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1849870A1 (en) * 1995-02-20 2007-10-31 The Walter And Eliza Hall Institute Of Medical Research Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (IDDM)
EP0821006B1 (de) * 1996-07-26 2004-04-21 Aventis Pharma Deutschland GmbH Insulinderivate mit erhöhter Zinkbindung
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
ES2266187T3 (es) 2000-03-24 2007-03-01 Genentech, Inc. Uso de la insulina para el tratamiento de trastornos del cartilago.
BR0215029A (pt) * 2001-12-20 2005-12-20 Lilly Co Eli Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus
BRPI0409600A (pt) * 2003-04-29 2006-04-18 Lilly Co Eli análogo de insulina, composição, método de tratamento de hiperglicemia, e, análogo de pró-insulina
US8343914B2 (en) * 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
WO2008015099A2 (en) 2006-07-31 2008-02-07 Novo Nordisk A/S Pegylated, extended insulins
KR101729986B1 (ko) * 2006-09-22 2017-04-25 노보 노르디스크 에이/에스 프로테아제 내성 인슐린 유사체
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
WO2008132224A2 (en) 2007-04-30 2008-11-06 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
DK2910570T3 (en) 2008-03-18 2017-01-30 Novo Nordisk As Protease-stabilized acylated insulin analogues.
US8993516B2 (en) * 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
CA2722168A1 (en) * 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
KR20120129875A (ko) 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
US8399407B2 (en) * 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
CA2783763A1 (en) 2009-12-11 2011-06-16 Case Western Reserve University Insulin analogues with chlorinated amino acids
WO2012123519A2 (en) * 2011-03-15 2012-09-20 Novo Nordisk A/S Human insulin analogues and derivatives comprising cysteine substitutions
US9481721B2 (en) 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
MX366636B (es) 2013-10-07 2019-07-17 Novo Nordisk As Nuevo derivado de un análogo de insulina.
CN104017809A (zh) * 2014-06-05 2014-09-03 山东省农业科学院生物技术研究中心 改造的人Insulin蛋白表达基因及表达方法
KR102569743B1 (ko) 2014-10-06 2023-08-23 케이스 웨스턴 리저브 유니버시티 이상 단일 사슬 인슐린 유사체
US10627415B2 (en) 2015-03-12 2020-04-21 Board Of Trustees Of Michigan State University Compositions and methods for diagnosing, monitoring, and treating an autoimmune disease
JP2018531007A (ja) * 2015-09-24 2018-10-25 ハンミ ファーマシューティカル カンパニー リミテッド インスリンの製造方法
TWI700091B (zh) 2016-12-16 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 含胰島素醫藥組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
US4569791A (en) * 1984-06-14 1986-02-11 Eli Lilly And Company Anti-diabetic compounds
US4581165A (en) * 1984-06-14 1986-04-08 Eli Lilly And Company Anti-diabetic compounds
US4569792A (en) * 1984-06-14 1986-02-11 Eli Lilly And Company Anti-diabetic compounds
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
DK129385A (da) * 1985-03-22 1986-09-23 Novo Industri As Peptider og fremstilling deraf
ZA877505B (en) * 1986-10-14 1989-05-30 Lilly Co Eli Process for transforming a human insulin precursor to human insulin
US4992418A (en) * 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogue-[10-Aspartic Acid-B]Human Insulin
ES2061797T3 (es) * 1988-06-23 1994-12-16 Hoechst Ag Mini-proinsulina, su preparacion y empleo.
DE3844211A1 (de) * 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DK134189D0 (da) * 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
DE3936876A1 (de) * 1989-11-06 1991-05-23 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5130236A (en) * 1989-12-07 1992-07-14 Eli Lilly And Company Process for producing des(64,65)-proinsulin
US5139716A (en) * 1990-02-20 1992-08-18 Loral Aerospace Corp. Method of fabricating coolable ceramic structures

Also Published As

Publication number Publication date
HU9203688D0 (en) 1993-03-29
IL103849A0 (en) 1993-04-04
CN1072723A (zh) 1993-06-02
EP0544466A1 (en) 1993-06-02
FI925343L (fi) 1993-05-27
NO924525L (no) 1993-05-27
BR9204542A (pt) 1993-06-01
JP3304442B2 (ja) 2002-07-22
ZA928916B (en) 1994-05-18
US5698669A (en) 1997-12-16
KR930009591A (ko) 1993-06-21
US5491216A (en) 1996-02-13
MX9206724A (es) 1993-05-01
FI925343A0 (fi) 1992-11-25
FI925343A7 (fi) 1993-05-27
HUT63457A (en) 1993-08-30
JPH05286998A (ja) 1993-11-02
NZ245170A (en) 1994-07-26
CZ342492A3 (en) 1993-06-16
NO924525D0 (no) 1992-11-24
AU2857692A (en) 1993-05-27
CA2083360A1 (en) 1993-05-27

Similar Documents

Publication Publication Date Title
DK0510774T3 (cg-RX-API-DMAC7.html)
DE4291016T1 (cg-RX-API-DMAC7.html)
EP0503236A3 (cg-RX-API-DMAC7.html)
CH0502314H1 (cg-RX-API-DMAC7.html)
EP0497593A3 (cg-RX-API-DMAC7.html)
DE4290581T1 (cg-RX-API-DMAC7.html)
DE4290260T1 (cg-RX-API-DMAC7.html)
DE4290891T1 (cg-RX-API-DMAC7.html)
DE4193446T1 (cg-RX-API-DMAC7.html)
EP0502544A3 (cg-RX-API-DMAC7.html)
DK0520893T3 (cg-RX-API-DMAC7.html)
DE4290032T1 (cg-RX-API-DMAC7.html)
DE4291827T1 (cg-RX-API-DMAC7.html)
DE4290190T1 (cg-RX-API-DMAC7.html)
DE4290288T1 (cg-RX-API-DMAC7.html)
ECSDI910052S (cg-RX-API-DMAC7.html)
ECSM91556U (cg-RX-API-DMAC7.html)
ECSM91575U (cg-RX-API-DMAC7.html)
DK77391D0 (cg-RX-API-DMAC7.html)
ECSM91524U (cg-RX-API-DMAC7.html)
ECSM91539U (cg-RX-API-DMAC7.html)
ECSM91562U (cg-RX-API-DMAC7.html)
CN3009741S (cg-RX-API-DMAC7.html)
AU1090492A (cg-RX-API-DMAC7.html)
CN3009775S (cg-RX-API-DMAC7.html)